newsfilter
← Latest News
Business Wire·

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month treatment with option of at-home administration after first dose – – CHB affects approximately 1.7